S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study

Inclusion criteria

• Joined the study voluntarily and signed informed consent form;
• Age 18-75

.Presence of at least one index lesion measurable by CT scan or MRI

• recurrence/metastasis of Esophageal carcinoma or gastroesophageal cancer confirmed by pathology
• No radiotherapy, chemotherapy or other treatments prior to enrollment
• PS ECOG 0-1
• Life expectancy of more than 3 months
• ANC≥2×109/L，PLT≥100×109/L，Hb≥90g/L

• Cr≤1.0×UNL
• TBIL≤1.25×UNL； ALT/AST≤2.5×UNL，with hepatic metastases ALT/AST≤5.0×UNL；AKP≤2.5×UNL

Exclusion criteria

• there is radical cure of the cancer

• uncontrolled chronic diarrhea and esophageal obstruction
• Neurological or mental abnormalities Influence of cognitive ability include central nervous system metastases
• Severe complication(s), e.g.,uncontrolled active infection,myocardial infarction,hypertension,arrhythmia,stenocardia
• Patient who has metastasis except cured skin basal cell carcinoma and carcinoma in situ of cervix
• accept other antitumor therapy •Female patients during their pregnant and lactation period, or patients without contraception